The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The respiratory disease vaccine market has experienced a consistent upward trajectory in recent years. From $68.4 billion in 2023, it is slated to grow to $69.99 billion in 2024, exhibiting a Compound Annual Growth Rate (CAGR) of 2.3%. The growth in the historic period can be attributed to the increasing prevalence of respiratory diseases, heightened public vaccination awareness, robust public health initiatives, and a growing demand for effective and tolerable vaccines.

Anticipating Steady Growth: Projections for the Future

Forecasted Growth in the Next Few Years:

• The respiratory disease vaccine market is expected to witness continued growth, reaching $76.18 billion in 2028.
• The forecasted Compound Annual Growth Rate (CAGR) for this period is 2.1%.

Drivers of Future Growth:

• Aging population contributing to increased demand for respiratory disease vaccines.
• Rising healthcare spending, investments in vaccines, and a focus on pandemic preparedness.

Trends Shaping the Future:

• Innovation in vaccine development.
• Collaborative research initiatives.
• Advancements in the field of respiratory disease vaccines.
• Drug approvals driving market dynamics.

Smoking’s Toll: A Boost to the Respiratory Disease Vaccine Market

Rising Incidence of Smoking:

• Smoking is linked to various health risks, including tracheitis, heart disease, stroke, and cancer.
• Respiratory disease vaccines offer protection against specific infections for smokers.

Impact on Market Growth:

• Statistics Canada reports a 5.8% increase in cigarette production in July 2022 compared to the previous year.
• The total number of cigarettes sold rose by 1.3% in June 2022, reaching 1.4 billion.
• The surge in smoking incidence is driving the growth of the respiratory disease vaccine market.

Read More On The Respiratory Disease Vaccine Market Report 2023 – https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Industry Leaders: Paving the Way for Improved Solutions

Market Dominance by Major Players:

• Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., and other industry leaders play a pivotal role in market growth.
• The presence of established pharmaceutical companies ensures a robust market landscape.

Striving for Enhanced Efficacy:

• Companies focus on creating innovative products to enhance efficacy and provide improved solutions.
• Pfizer Inc. receives FDA approval for ABRYSVO, a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for individuals aged 60 and older.
• ABRYSVO maximizes immunity to RSV A and B varieties, proving to be safe and productive in clinical trials.

Strategic Acquisitions: Advancing Vaccine Development

GSK’s Acquisition of Affinivax Inc.:

• GSK PLC acquires Affinivax Inc., a US-based clinical-stage biotechnology company, in August 2022.
• The acquisition strengthens GSK’s commitment to innovate drugs and vaccines.
• Focus on developing a next-generation 24-valent pneumococcal vaccine candidate (AFX3772).

Market Segmentation: Understanding the Landscape

1) By Type:

• Respiratory disease vaccines segmented into viral, bacterial, and combination vaccines.

2) By Infection:

• Targeting COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, and other infections.

3) By Age:

• Tailoring vaccines for infants, adolescents, and adults.

4) By End-User:

• Utilization in clinics, hospitals, and other end-users.

Regional Dynamics: Asia-Pacific Leads, North America Grows Fastest

Asia-Pacific’s Dominance:

• In 2023, Asia-Pacific emerged as the largest region in the respiratory disease vaccine market.
• A testament to the region’s significant contribution to overall market growth.

North America’s Rapid Growth:

• North America is expected to be the fastest-growing region in the forecast period.
• Reflects a burgeoning market with increasing demand for respiratory disease vaccines.

Request for A Sample Of The Global Respiratory Disease Vaccine Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=12924&type=smp

The Table Of Content For The Respiratory Disease Vaccine Market Include:
1. Respiratory Disease Vaccine Market Executive Summary
2. Respiratory Disease Vaccine Market Segments
3. Respiratory Disease Vaccine Market Size And Respiratory Disease Vaccine Market Growth Rate
4. Key Respiratory Disease Vaccine Market Trends
5. Major Respiratory Disease Vaccine Market Drivers
……
25. Key Mergers And Acquisitions In The Respiratory Disease Vaccine Market
26. Top Respiratory Disease Vaccine Companies
27. Respiratory Disease Vaccine Market Opportunities And Strategies
28. Respiratory Disease Vaccine Market, Conclusions And Recommendations
29. Appendix

The Respiratory Disease Vaccine Market Global Market Report 2023 covers regional data on key drivers, opportunities, and strategies for the seven major regions of the world that are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The report includes market size and forecast market shares for all the regions and countries concerning the major players of the respiratory disease vaccine market.

View More Reports Related To The Market –
Respiratory Disease Testing Global Market Report 2023

Respiratory Protection Equipment Global Market Report 2023

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2023

Contact us at
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model